1. Home
  2. CASS vs NGNE Comparison

CASS vs NGNE Comparison

Compare CASS & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cass Information Systems Inc

CASS

Cass Information Systems Inc

N/A

Current Price

$53.33

Market Cap

714.9M

ML Signal

N/A

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$26.20

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CASS
NGNE
Founded
1906
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
714.9M
744.9M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
CASS
NGNE
Price
$53.33
$26.20
Analyst Decision
Hold
Strong Buy
Analyst Count
2
10
Target Price
$59.50
★ $77.88
AVG Volume (30 Days)
54.3K
★ 247.4K
Earning Date
10-22-2026
11-12-2026
Dividend Yield
★ 2.37%
N/A
EPS Growth
★ 87.77
0.93
EPS
★ 1.48
N/A
Revenue
★ $190,750,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.52
N/A
P/E Ratio
$36.45
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$36.07
$15.93
52 Week High
$59.63
$43.66

Technical Indicators

Market Signals
Indicator
CASS
NGNE
Relative Strength Index (RSI) 38.30 33.33
Support Level $52.75 $24.88
Resistance Level $54.44 $26.40
Average True Range (ATR) 0.90 1.93
MACD -0.03 -0.19
Stochastic Oscillator 18.93 15.64

Price Performance

Historical Comparison
CASS
NGNE

About CASS Cass Information Systems Inc

Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution, and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. Additionally, the firm has a banking subsidiary, offering banking services mainly to privately held businesses in the St. Louis metropolitan area and restaurant franchises and faith-based ministries within the United States. The company operates in two reportable segments: Information Services, which generates the maximum revenue, and Banking Services.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: